Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
06 août 2021 06h00 HE
|
Mersana Therapeutics, Inc.
Initiated UPGRADE, a Phase 1 platinum combination cohort in platinum-sensitive ovarian cancerCompany plans to disclose target and preclinical data for XMT-2056, first Immunosynthen STING-agonist ADC,...
Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
04 août 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates
30 juil. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer
28 juil. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference
26 mai 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
10 mai 2021 16h01 HE
|
Mersana Therapeutics, Inc.
- Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer- Ended first quarter of 2021 with $228 million in cash CAMBRIDGE, Mass., May 10, 2021 ...
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates
03 mai 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
28 avr. 2021 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer
26 avr. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
10 avr. 2021 09h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...